Resmed tanks overnight on trial failure

The SMH reports that "Medical device maker ResMed has said a major clinical trial that sought to show its sleep therapy products protected heart attack victims, actually put their lives at further risk. The shock clinical trial result will be a major disappointment for ResMed investors who were counting on a positive result to open the door for the company to play a role in the treatment of heart failure, which costs the US government alone $US35 billion each year. (VIEW LINK)